Stopping Tirzepatide (Zepbound): Weight Regain, Side Effects and Cold Turkey

Yes, most people regain weight after stopping tirzepatide, and they start soon. In SURMOUNT-4, the trial built to test this, people who had lost about 21% on Zepbound’s active ingredient were switched to placebo injections. Within 28 weeks they had put back 10% of their body weight, and 14% by the end of the year. Only 16.6% kept at least four-fifths of what they had lost, against 89.5% of those who stayed on the drug.^[1] Stopping abruptly is how that trial did it, and the drug label has no taper schedule. The usual side effects fade as the drug clears over the following weeks. What tends to come back is appetite, and then weight.

How much weight comes back after stopping Zepbound

SURMOUNT-4 enrolled 783 adults who met the obesity criteria, or carried excess weight along with a related health problem such as high blood pressure. Diabetes was an exclusion. Everyone took tirzepatide for 36 weeks and worked up to the highest dose they could tolerate, 10 mg or 15 mg. Then 670 were randomized: half kept injecting tirzepatide and half were switched straight to placebo for 52 weeks, with no step-down in between. Both groups got the same diet and activity counseling throughout, a 500-calorie daily deficit and at least 150 minutes of activity a week.^[1] That makes the placebo arm the closest thing we have to a controlled test of stopping tirzepatide cold turkey.

Two things in that table matter more than the headline. First, regain was front-loaded. About seven-tenths of the year’s gain in the placebo group had already happened by week 64, 28 weeks after the switch, and the remaining 24 weeks added about four points more.^[1] So the first six months off the drug are when the scale moves fastest. Second, the placebo group did not end up back where it started. A year after stopping, the average participant was still 9.9% below their original weight.^[1]

Pooled data point the same way. A 2026 reanalysis of six studies of people stopping semaglutide or tirzepatide estimated regain at about 1 kg a month. On a straight-line model, half the lost weight would be back by about seven and a half months. The authors warn that anything past a year is extrapolation, and after adjustment they found no clear difference between the two drugs.^[6]

Will you gain all of it back?

Not on average, at least not within a year. The trial also reported how many people were still below their starting weight at week 88, counting the weight lost on the drug before the switch.

Seven in ten people who stopped still had a meaningful loss of at least 5% a year later, and close to half kept 10%.^[1] The range between people was wide. A separate analysis of the placebo arm grouped those who had lost at least 10% by how much came back. Most regained a quarter or more within the year, but 54 of 308 regained less than a quarter.^[4] No one has yet shown which baseline traits predict who those people will be. The 2026 reanalysis found a larger first loss leaning toward faster regain, but the uncertainty band included no effect.^[6]

What happens to blood pressure, waist and blood sugar

Weight is not the only thing that drifts back. Compared with the people who kept taking tirzepatide, the placebo group had significantly worse changes from week 36 to week 88 in blood pressure, HbA1c, fasting glucose, insulin and blood lipids.^[1] The investigators put it plainly in their discussion:

However, much of their initial improvement in cardiometabolic risk factors had been reversed.

— Aronne et al., SURMOUNT-4, JAMA 2024

The later analysis of the placebo arm found that how far these markers moved tracked how much weight came back. People who regained the least saw the smallest changes, and in that group waist size, non-HDL cholesterol and fasting insulin were not significantly different a year later.^[4] We walk through that gradient, and its limits, in what happens when you stop a GLP-1. Whether a year of regain carries a cardiovascular cost beyond these numbers is an open question, covered in the cardiovascular cost of stopping.

Side effects after stopping tirzepatide, and stopping cold turkey

Neither tirzepatide label describes a withdrawal syndrome, and the trial evidence points the other way. In the SURMOUNT-4 year after the abrupt switch, the placebo group reported slightly fewer adverse events overall than the group still on the drug, and markedly less nausea, vomiting and diarrhea.^[1][2]

For comparison, 35.5% of the same people had nausea during the first 36 weeks on the drug.^[1] The Mounjaro label says most nausea, vomiting and diarrhea happened during dose escalation and eased over time.^[3] The three gallbladder cases in the placebo arm are too few to draw conclusions from, but they are worth knowing about. Gallbladder pain, especially in the upper right abdomen, needs medical attention whether you are on the drug or off it.

What people describe instead is the effect wearing off: hunger and larger portions coming back. The labels explain why. GLP-1 is described as “a physiological regulator of appetite and caloric intake,” and tirzepatide acts on that receptor.^[2] No withdrawal trial has measured appetite on a validated scale, so there is no week by which it returns. The regain curve above is the best indirect measure.

How long tirzepatide stays in your system

According to the Zepbound label, the body clears half of any dose in roughly five to six days.^[2] Roughly half the drug is gone a week after the last shot. Pharmacologists generally treat five half-lives as the point where a medicine is essentially gone, which for tirzepatide works out to roughly a month. Side effects caused by the drug would be expected to fade over those same weeks. The weight trajectory in SURMOUNT-4 kept moving for a year, long after the drug was gone, so it reflects the body’s own regulation, not leftover drug. The reasons that regulation pushes back are covered in why weight loss plateaus and returns.

Is tapering better than stopping abruptly?

Nobody knows yet. The Zepbound and Mounjaro labels contain no taper, no stopping schedule and no instructions for restarting after a long break.^[2][3] A 2026 review describes the field as operating “in the absence of validated tapering strategies.”^[7] We found no published trial that compares a gradual tirzepatide step-down against an abrupt stop. The nearest evidence is a different question: whether a lower dose holds weight as well as the full dose. That is below. If you want to come off gradually, raise it with your prescriber, because there is no evidence-based schedule to follow on your own. Our review of stopping as a clinical transition covers what a planned handover can include.

Missed doses are not the same as stopping

If the problem is a late shot, not a decision to stop, the label is specific:

If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.

— Zepbound prescribing information, section 2.3

Mounjaro’s label uses the same wording.^[3] Neither label says what to do after several weeks off. Jumping straight back to a full dose once your body has lost its tolerance is a question for your prescriber; work it out together first. The label’s step-up schedule, which begins with four weekly 2.5 mg shots, is on our Zepbound dosing page.^[2]

Stopping Mounjaro when you have type 2 diabetes

This is the case where stopping without a plan carries the most risk. Mounjaro’s first approved use is glucose control in type 2 diabetes. Its second is cutting the risk of heart attack, stroke and death from heart disease in people with that diagnosis whose heart risk is high.^[3] Stopping removes both effects. SURMOUNT-4 excluded people with diabetes, and we found no tirzepatide withdrawal trial in type 2 diabetes. Even in SURMOUNT-4’s non-diabetic participants, HbA1c rose after the switch, and it rose more in those who regained more.^[1][4]

Other diabetes drugs may also have been adjusted around tirzepatide. The label warns that pairing tirzepatide with insulin or a sulfonylurea raises the chance of low blood sugar, and that prescribers can offset this by cutting the dose of those other drugs.^[3] If your insulin or sulfonylurea dose was cut when you started, removing tirzepatide changes that balance. Tell whoever manages your diabetes before the last pen runs out, not after, and ask whether your glucose monitoring should change.

Compounded tirzepatide: same molecule, less certainty

If you are stopping compounded tirzepatide, the trial results above apply as far as the product actually contained tirzepatide at the stated strength. The molecule and its half-life are the same. What differs is how sure you can be. FDA points out that compounded versions carry no approval, which means nobody at the agency checks them for safety, effectiveness or quality before they reach patients. It has also documented fraudulent compounded tirzepatide and dosing errors with compounded GLP-1 products.^[11] If your doses were unusual or the vial’s strength was uncertain, tell the next prescriber what you were actually injecting. Our review of compounded tirzepatide safety covers the quality questions.

What the evidence says helps keep weight off after stopping

This is where the evidence is thinner than the questions. Here is what has actually been tested.

Staying on a lower dose. SURMOUNT-MAINTAIN took people who had lost weight on their top tirzepatide dose for 60 weeks and randomized them to stay on it, drop to 5 mg, or switch to placebo. At week 112 they were 21.9%, 16.6% and 9.9% below their starting weight. From week 84, anyone who had regained more than half their loss could get rescue tirzepatide, and 8%, 25% and 67% of the three groups received it.^[5] So a lower dose held much more than stopping, though less than the full dose. Lilly funded the trial. The details are in our write-up of the maintenance-dose trial.

Exercise, especially supervised exercise. The best randomized evidence comes from a Danish trial of liraglutide, an older daily GLP-1 drug. It was not run with tirzepatide or semaglutide. After an eight-week diet in which participants lost 13.1 kg, they were randomized for a year to supervised exercise, liraglutide, both, or placebo. Against placebo, exercise alone kept off 4.1 kg more, liraglutide 6.8 kg more, and the combination 9.5 kg more. The combination also cut body fat by about twice as much as either alone.^[8] The more relevant follow-up came a year after all treatment ended. People who had been on liraglutide alone regained 6.0 kg more than those who had done supervised exercise. The exercise group’s weight and body composition held steady.^[9] Whether this carries over to tirzepatide has not been tested, but it is the strongest controlled evidence that an exercise habit built during treatment outlasts the drug.

Resistance training and protein while you are still on the drug. A 2025 joint advisory from four obesity and nutrition societies lists preserving muscle and bone “through resistance training and appropriate diet” as a priority during GLP-1 treatment. The same advisory names nutrition for keeping weight off after stopping as an area still needing study.^[10] In other words, building muscle and eating enough protein make sense while you are on the drug, but there is no trial yet on the best diet for after you stop. Our article on protein targets covers the during-treatment side.

Lifestyle support alone, after stopping. SURMOUNT-4 is a sobering check here. Its placebo group kept getting diet and activity counseling and still regained 14% in a year.^[1] In the 2026 reanalysis, lifestyle support after stopping leaned toward slower regain, but the estimate was too imprecise to rely on.^[6] Counseling helps less than people hope, and planning before the last dose helps more than a scramble after it. The semaglutide version of that plan, which is largely the same, is in stopping Ozempic or Wegovy.